Desoxyn (Methamphetamine HCI) Central nervous system agent CNS stimulant Attention-deficit disorder with hyperactivity and as short-term adjunct in exogenous obesity. (Children >6 years) Initially 5mg once or twice daily. May increase dose in 5mg increments at weekly intervals. Usual effective dose 20 to 25 mg/day. Interrupt treatment occasionally to determine whether continuation necessary. Category C Increase blood pressure, Palpitations, Diarrhea, Constipation, dry mouth, Impotence, dizziness, Insomnia, tremor, headache, restlessness, suppression of growth in children with long-term use. Pregnancy Risk Categories defined: A: Studies in pregnant women failed to show a risk to the fetus in the first trimester - with no evidence of risk in the later trimesters. B: Animals studies indicate no adverse effect to the fetus, but there are no adequate, clinical studies in pregnant women. C: Animal studies have shown an adverse effect on the fetus, but there are no adequate, clinical studies in humans. Despite potential risks, the drug may be useful in pregnant women. D: There is evidence of risk to the human fetus, but the potential benefits of use in pregnant women may be acceptable, despite potential risks. X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any potential benefit from using the drug in pregnant women, regardless of trimester. NR: Not rated (i.e., no information available at this time as to the potential risks or benefits).